

Luigi Francesco Iannone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903388/publications.pdf>

Version: 2024-02-01

29
papers

695
citations

567281
15
h-index

580821
25
g-index

30
all docs

30
docs citations

30
times ranked

853
citing authors

#	ARTICLE	IF	CITATIONS
1	Microbiota-gut brain axis involvement in neuropsychiatric disorders. Expert Review of Neurotherapeutics, 2019, 19, 1037-1050.	2.8	116
2	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. Frontiers in Neurology, 2018, 9, 1067.	2.4	60
3	Can we “seize” the gut microbiota to treat epilepsy?. Neuroscience and Biobehavioral Reviews, 2019, 107, 750-764.	6.1	60
4	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Current Medical Research and Opinion, 2020, 36, 1457-1463.	1.9	40
5	Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE, 2020, 15, e0241575.	2.5	38
6	First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. Epilepsia, 2021, 62, 529-541.	5.1	35
7	Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. CNS Drugs, 2021, 35, 609-618.	5.9	34
8	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Frontiers in Pharmacology, 2021, 12, 684638.	3.5	33
9	Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs, 2022, 36, 191-202.	5.9	32
10	The potential role of interventions impacting on gut-microbiota in epilepsy. Expert Review of Clinical Pharmacology, 2020, 13, 423-435.	3.1	25
11	Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. European Journal of Neurology, 2022, 29, 1505-1513.	3.3	25
12	Clinically relevant drug interactions between statins and antidepressants. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 227-239.	1.5	24
13	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review. Dermatologic Therapy, 2019, 32, e12748.	1.7	23
14	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Frontiers in Neurology, 2021, 12, 673135.	2.4	23
15	The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a “real world” context: focus on temporal lobe epilepsy. Journal of the Neurological Sciences, 2020, 415, 116903.	0.6	18
16	Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia, 2022, 42, 1323-1330.	3.9	18
17	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. Gastric Cancer, 2021, 24, 765-779.	5.3	12
18	Status epilepticus in pregnancy: a literature review and a protocol proposal. Expert Review of Neurotherapeutics, 2022, 22, 301-312.	2.8	12

#	ARTICLE	IF	CITATIONS
19	The microbiota-gut-brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models. Bioengineering and Translational Medicine, 2022, 7, .	7.1	10
20	Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). PLoS ONE, 2018, 13, e0205134.	2.5	9
21	Renal denervation for resistant hypertension. The Cochrane Library, 2021, 2021, CD011499.	2.8	9
22	A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report. Current Drug Safety, 2020, 15, 69-72.	0.6	7
23	Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE). Epilepsy and Behavior, 2021, 116, 107804.	1.7	7
24	Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. Expert Opinion on Pharmacotherapy, 2019, 20, 25-39.	1.8	6
25	Emerging Pharmacological Treatments for Migraine in the Pediatric Population. Life, 2022, 12, 536.	2.4	6
26	Management of status epilepticus in patients with liver or kidney disease: a narrative review. Expert Review of Neurotherapeutics, 2020, 21, 1-14.	2.8	4
27	Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system. PLoS ONE, 2021, 16, e0249681.	2.5	4
28	Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief. Temperature, 2023, 10, 50-66.	3.0	3
29	Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly. Expert Review of Neurotherapeutics, 2019, 19, 1165-1165.	2.8	2